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ABSTRACT
Multivariate analysis was performed to determine the independent factors affecting the risk of acute GVHD
(aGVHD) grades II to IV and extensive chronic GVHD (cGVHD) and the rate of survival in 481 recipients of
T cell–depleted (TCD) marrow allografts who received transplants at a single center between 1991 and 2000. All
patients received grafts partially depleted of CD3+ T cells by complement-mediated lysis using 2 narrow-specificity
monoclonal antibodies (MoAbs), T10B9.1A-31 (n = 400) or Muromonab-Orthoclone OKT3 (n = 81). Factors con-
sidered in the analysis included patient/donor sex, age, cytomegalovirus (CMV) status, and ABO blood group along
with T-cell dose, disease and disease status, donor relationship, HLA antigen (Ag) mismatch (MM), growth-factor
use, anti-thymocyte globulin use, year of transplantation, and the MoAb used for TCD. The results showed an asso-
ciation of HLA MM with an increased relative risk (RR) of aGVHD for recipients of grafts from related donors that
were ≥2 Ag MM (n = 73, RR = 2.09, P = .005), matched unrelated (UR) donors (n = 130, RR = 1.98, P = .004), and
≥2 Ag MM UR donors (n = 34, RR = 2.68, P = .003) compared with the baseline matched-sibling group (n = 121).
No increased risk of aGVHD was seen for 0 to 1 Ag MM family donors (n = 24) or 1 Ag MM UR donors (n = 99).
aGVHD risk was increased with minor, but not major or major-minor, ABO disparity (RR = 2.0, P = .003) compared
with that of ABO-identical pairs. We found less effective TCD and resultant higher T-cell dose for recipients of
grafts that were T cell depleted using OKT3. However, the use of OKT3 and not the T-cell dose was associated
with increased aGVHD risk (RR of 1.84, P = .001). Increased risk of extensive cGVHD was associated with patient
age of >20 years (RR = 2.2, P < .0001) and with CMV status (positive patient/negative donor, RR = 1.9, P = .002).
Decreased survival was associated with older age (>20 years), a ≥2 Ag MM related donor, a 1 or ≥2 Ag MM UR
donor, risk group, and a CMV-positive patient/-negative donor pair. There was no difference in survival for 0 to
1 Ag MM related or matched UR donors compared with the baseline group. These data indicate that there are
quantitative as well as potential qualitative differences in outcome depending on the TCD method. Expected and
unexpected risk factors for GVHD and survival were associated with partial TCD. Our data support the considera-
tion of ABO match in donor selection, the preferential selection of CMV-positive donors for CMV-positive recipi-
ents, and the acceptance of 1 but not ≥2 Ag HLA MM donors.
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INTRODUCTION
Graft-versus-host disease (GVHD) is one of the more
serious morbidities associated with bone marrow transplan-
tation (BMT) and as such serves as a major barrier to trans-
plantation from unrelated or partially matched family member
donors [1-3]. T-cell depletion (TCD) of marrow allografts
by almost every method described reduces the incidence and
severity of acute GVHD (aGVHD), and, if depletion is
extensive, the incidence of chronic GVHD (cGVHD) may
be reduced as well [4,5]. However, despite the reduction in
GVHD, TCD has not resulted in an overall increase in sur-
vival in most reported studies [3,4]. The failure to improve
survival rates may, in part, result from one or all of the risks
associated with TCD, namely a higher rate of graft failure,
an increase in relapse for some diseases, and a delay in
immune reconstitution compared with conventional allo-
grafts [4,6]. The likelihood of these risks is not the same for
all forms of TCD [4]. Graft rejection and leukemia relapse
appear to be more likely when TCD is rigorous, supporting
the premise that both effects may be due to loss of alloreactive
T cells in the graft that could eliminate residual host-derived
T cells or due to leukemia that survives the conditioning reg-
imen [7]. The effect of TCD on immune reconstitution
compared with conventional allografts also varies depending
primarily on the degree of TCD [8]. Relatively modest
delays may be seen for TCD protocols that do not require
additional immune suppression for GVHD prophylaxis [8-10].
However, profound delays in immune reconstitution may be
seen in the allogeneic setting when TCD is nearly complete
[11,12]. The combination of less rigorous TCD and addi-
tional immune suppression to prevent GVHD or promote
engraftment can also result in a longer period of immune
deficiency compared to that seen in recipients of conven-
tional marrow allografts [10,13-15].
A recent International Bone Marrow Transplant Registry
(IBMTR) study has compared the outcome of unrelated
donor transplantation performed using different forms of
TCD with that performed using non-TCD transplantation
[4]. TCD methods were categorized into 2 main groups,
those narrowly targeting T cells and those that removed a
broader spectrum of cell types, including T cells. It was
found that all methods of TCD reduced aGVHD risk and
did not result in a higher rate of relapse compared with con-
ventional transplantation performed using cyclosporine and
methotrexate. No signiﬁcant differences in outcomes were
seen between TCD methods within the 2 main groups, but
patients receiving grafts that were T cell depleted using
narrow-specificity techniques had lower treatment failure
risks compared with patients receiving transplants that were
T cell depleted using broad techniques. It was speculated
that there might be differences between methods of TCD
within these 2 main categories that could not be ascertained
due to the limitations imposed by the information available
for the analysis. Our method of TCD using the narrow-
specificity antibody T10B9-1A.31 (T10B9) has resulted in a
reduction in GVHD incidence and severity compared with
conventional allografts, without significant graft rejection,
even in a setting of alternative donor transplantation [16-20].
Recently, we have modiﬁed our method of TCD to use a sec-
ond narrow-specificity antibody, Muromonab-Orthoclone
OKT3 (OKT3) (Ortho Biotech, Raritan, NJ), providing us the
opportunity to compare outcomes using these 2 approaches
at a single center as well as to determine other significant
factors that affect outcome in our patient group. To this end,
we performed a retrospective study of our patients treated
over the past 9 years with a standardized conditioning regi-
men and GVHD prophylaxis schedule that includes a par-
tially TCD BMT. We compared the TCD efﬁciency of the
2 monoclonal antibodies (MoAbs) and performed a multi-
variate analysis to determine factors associated with aGVHD
(grades II-IV), extensive cGVHD, and survival.
PATIENTS AND METHODS
Patients
Between June 1991 and June 2000, a total of 503 patients
received primary transplants of TCD marrow for malignant
and nonmalignant diseases. All transplantation was per-
formed at the Medical College of Wisconsin at Froedtert
Memorial Lutheran Hospital, John L. Doyne Hospital, or
the Children’s Hospital of Wisconsin. Informed consent was
obtained from each patient (or patient’s guardian), and all
treatment was administered under approved protocols of the
Institutional Review Committee. Because T-cell content of
the graft was a primary analysis factor, only the 481 patients
for whom evaluable data for T-cell dose was obtained from
limiting dilution assay (LDA) were included in the analysis.
Six patients died prior to transplantation; thus, LDA was not
performed, and 15 patients were excluded because 1 or
more assay attempts failed for technical reasons. One addi-
tional patient was excluded who received a transplant from
an identical twin, and 2 patients were included who received
transplants in early 1990 and had retrospective LDA data.
All patients received marrow that was T cell depleted by
complement-mediated lysis using either T10B9 (n = 400) or
OKT3 (n = 81) MoAb to remove CD3+ T lymphocytes.
Patients received a standard conditioning regimen of
intravenous cytarabine (3 g/m2 every 12 hours for 6 doses
on days –7 to –4), cyclophosphamide (45 mg/kg given
6 hours after the second and fourth doses of cytarabine),
methylprednisolone (a total of 2 doses, 1 gm/m2 at 12-hour
intervals on days –2 and –1), and 13.3 or 14 Gy total body
irradiation [21]. The cytarabine dose was reduced 25% to
50% for those patients older than 40 years (n = 76) at the
discretion of the attending physician. Patients with aplastic
anemia were treated in an identical fashion, with the excep-
tion that 16 of the 32 patients were given anti-thymocyte
globulin (ATG) (Upjohn, Pharmacia, Peapack, NJ) at a dose
of 15 mg/kg per day on days 4 through 10 (total 7 doses) as
a result of a protocol modiﬁcation made in August 1994 to
promote engraftment [22].
All patients received GVHD chemoprophylaxis consist-
ing of cyclosporine administered as an intravenous infusion
beginning day –1 at 3 mg/kg per day and eventually changed
to a corresponding oral dose when tolerated. Recipients of
allografts from haplotype identical donors (n = 54) received
ATG, 15 mg/kg per day for either 7 or 14 days beginning on
day +4. Methylprednisolone was given in 2 daily doses of
1 mg/kg per day on days +2 through +17 and 1 dose on day
+18 and then tapered through day +35. An additional
11 recipients of unrelated marrow received an identical
course of ATG due either to presence of a 1-antigen (Ag)
C.A. Keever-Taylor et al.
622
HLA mismatch (MM) or because TCD achieved less than a
1.0 log reduction, as measured by ﬂow cytometric analysis.
No patients received ATG before transplantation.
Engraftment was defined as the first of 3 consecutive
days in which the absolute neutrophil count (ANC) was
≥500/mm3. Trilineage engraftment was documented by
bone marrow examination in the majority of patients 3 to
4 weeks after transplantation. Follow-up marrow studies
were done at 100 days, 6 months, 1 year, and at least yearly
after transplantation, whenever possible, to evaluate
engraftment and disease status. Durable engraftment was
confirmed by cytogenetic analysis, restriction fragment
length polymorphism (RFLP) studies, or analysis of vari-
able number of tandem repeats (VNTRs) in blood or mar-
row samples to distinguish donor from recipient cells.
Patient, donor, and graft characteristics that were consid-
ered in the analysis are listed in Table 1.
Factors Assessed
Outcomes. The depleting efﬁciencies of the 2 antibodies
measured as log depletion were compared. aGVHD grades
II to IV, extensive cGVHD, and overall survival rates were
also assessed. aGVHD was graded as 0 to IV according to
criteria of Glucksberg and colleagues, whereas cGVHD was
deﬁned as none, limited, or extensive [23,24]. Patients who
had evidence of engraftment were evaluable for aGVHD
(n = 446). Nonevaluable patients included 15 patients who
died of infection or conditioning toxicity prior to engraft-
ment and 20 patients (4.3%) with primary graft failure,
likely due to immunologic rejection. Patients who engrafted
and also survived more than 90 days were evaluable for
cGVHD (n = 361). The median follow-up time of survivors
was 51 months (range, 4-124 months).
Variables. The variables that were assessed in this analy-
sis for all outcomes are included in Table 1. The analysis
included 2 strata based on the median of the sample with
respect to the age of the patient and the donor: aged
≤20 years versus >20 years and ≤40 years versus >40 years,
respectively. Risk strata were deﬁned based on disease stage
for leukemia patients as standard (complete response [CR1]
or first chronic phase [CP1]), intermediate (first partial
response [PR1], ﬁrst relapse [Rel1], second or higher com-
plete response [CR2+], CP2+, first accelerated phase
chronic myeloid leukemia [CML] [AP1]), or high (Rel2+,
AP2, blast-phase CML, or never in remission). Lymphoma
patients were stratified as intermediate (CR2+) or high
(relapsed or refractory). Myelodysplastic syndrome (MDS)
patients with only refractory anemia were classiﬁed as inter-
mediate risk; the remainder were considered high risk
because of their overall inferior survival probability with
allogeneic transplantation compared with standard- or
intermediate-risk leukemia patients. Aplastic anemia (n =
32) patients were considered as standard risk, patients with
immune deficiencies (n = 12) and the remaining other
patients (n = 22) were grouped together because there was
no standard way to subgroup them for transplantation out-
come. Patients with acute lymphoblastic leukemia (ALL) in
CR1 were offered transplantation only in the presence of
other poor prognostic factors, such as the presence of Ph1
or other chromosomal abnormalities or age of <1 year. In
the majority of patients with acute nonlymphoblastic
Table 1. Patient, Donor, and Graft Characteristics*
Age at transplantation, y, median (range)
Patient 17 (<1-62)
Donor 36 (<1-68)
Year of transplantation
1991†-1993 144 (30%)
1994-1996 174 (36%)
1997-2000 163 (34%)
Sex match, patient/donor
Female/male 156 (32%)
Male/male‡ 123 (26%)
Male/female 106 (22%)
Female/female 96 (20%)
Diagnosis at transplantation
Acute leukemia‡ 248 (51%)
Chronic leukemia 91 (19%)
Lymphoma 46 (10%)
Aplastic anemia 32 (7%)
Other 34 (7%)
Diagnosis status risk at transplantation§
Standard‡ 140 (29%)
Intermediate 191 (40%)
High 116 (24%)
Other 34 (7%)
HLA matching and donor relationship
HLA identical siblings‡ 121 (25%)
0-1 Ag MM related 24 (5%)
≥2 Ag MM related 73 (15%)
Matched unrelated 130 (27%)
1 Ag MM unrelated 99 (21%)
≥2 Ag MM unrelated 34 (7%)
ABO Matching
Matched‡ 266 (55%)
Minor MM 96 (20%)
Major MM 90 (19%)
Major-minor MM 29 (6%)
CMV serology status, patient/donor
Positive/positive 86 (18%)
Positive/negative 98 (20%)
Negative/positive 86 (18%)
Negative/negative‡ 220 (46%)
Anti-thymocyte globulin
Yes 81 (17%)
No‡ 400 (83%)
Growth factor†
None‡ 258 (54%)
G-CSF 104 (22%)
GM-CSF 64 (13%)
G-CSF + GM-CSF 55 (11%)
Antibody used for TCD
T10B9‡ 400 (83%)
OKT3 81 (17%)
T-cell dose, median (range) 3.6 × 105/kg
(4.4 × 103-12.0 × 106)
*Except where noted, the data represent the number of patients in
each group and the percentage of the total patients in that group. 
†Two patients received transplants in 1990.
‡Reference group used for multivariate analysis.
§Standard risk: CR1, CP1 and SAA; intermediate risk: CR2+, PR1,
Rel1, AP1, and MDS refractory anemia; high risk: relapse or blast
phase or never in remission.
Considered only if initiated during the ﬁrst week posttransplantation.
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leukemia (ANLL) in CR1 (18 of 28), the ANLL was sec-
ondary to MDS and thus considered an indication of poor
prognosis, and some patients had other poor prognostic fea-
tures. Early in the program, patients with good-prognosis
ANLL were offered transplantation if HLA-identical sib-
lings donors were available. Year of transplantation was
stratiﬁed into 3 roughly equal groups: 1991 to 1993, 1993 to
1996, and 1997 to 2000.
HLA matching considered 8 alleles and was based on
HLA-A, HLA-B (class I) and HLA-DRB1, HLA-DQB
(class II). All patients were prospectively typed for class II at
the DNA level either using oligotyping [25] or DNA
sequencing [26]. All patients were typed for class I by serol-
ogy. A subset of partially matched family and unrelated
donor/recipient pairs were typed retrospectively (n = 130)
by full-length class I DNA sequencing [27] and/or 1-dimen-
sional isoelectric focusing [28] or prospectively (n = 65) by
exon 2 and 3 DNA sequencing. Antigen match was assigned
based on the highest level of typing performed considering
only the 8 alleles listed above.
ABO blood groups were considered matched if donor and
recipient were ABO identical. A minor ABO-mismatched
pair was defined when the donor uniquely possessed anti-
bodies specific for patient ABO antigens. A major ABO-
mismatched pair was defined when the patient uniquely
possessed antibodies specific for donor ABO antigens.
Major-minor ABO mismatch was deﬁned for donor/recipient
pairs that reciprocally possessed speciﬁc ABO antibody, eg,
type A donor to type B recipient or vice versa.
ATG use was considered in the analysis only if started
during the ﬁrst week posttransplantation. Patients typically
received ATG starting on day +4 for 7 or 14 days for reasons
described above.
Patients were stratiﬁed based on the type of growth fac-
tor used posttransplantation to facilitate engraftment.
Patients who did not receive growth factor or who started
growth factor after the ﬁrst week posttransplantation were in
the no growth factor group. Granulocyte-colony–stimulating
factor (G-CSF) was administered at 5 µg/kg subcutaneously
(SC) per day (or the total daily dose was rounded to the
nearest vial size, usually 480 µg). Granulocyte-macrophage
(GM)-CSF was administered at 250 to 500 µg/m2 SC per
day. A subset of 55 patients received both G-CSF and GM-
CSF during week 1 post-BMT as part of a clinical protocol.
When used, growth factors were administered until sus-
tained neutrophil engraftment was 1.0 × 109/L. The decision
to use growth factors for a given patient group and the
growth factor used was a function of the BMT program pol-
icy in place at the time of transplantation.
Prior to 1998, marrow grafts were depleted of T cells
using the αβ T-cell–receptor antibody, T10B9, and baby rab-
bit complement [29]. Due to the unavailability of an in vivo
grade of T10B9, TCD using OKT3 MoAb plus complement
was phased in beginning in July 1998 for recipients of hap-
loidentical marrow grafts and in October 1998 for all other
recipients. For both forms of TCD, the T-cell content was
measured both by ﬂow cytometry and by a sensitive LDA
for total clonable T cells [19]. The data were analyzed as
T cells/kg infused. The association of T-cell content and
outcome was assessed as both above and below the median
and per log of T cells infused.
Statistical Analysis
The univariate (unadjusted) probability of overall sur-
vival was calculated using the Kaplan-Meier product-limit
estimator. Cumulative incidences were estimated for
aGVHD and cGVHD. A Student t test was used to compare
the mean log depletion achieved with the 2 MoAbs and a
Mann Whitney to compare the postdepletion T-cell dose
with the 2 different antibodies. Association between the fac-
tors shown in Table 1 and the outcomes of interest were
evaluated in multivariate analyses using Cox proportional
hazards regression. Continuous variables were discretized in
the model based on the maximum partial likelihood ratio in
the Cox model. Data from patients who did not reach a
given endpoint were censored at the time of death, second
BMT or immunotherapy, or last assessment. Only those fac-
tors signiﬁcantly (P < .05) associated with an outcome were
retained in the ﬁnal models.
For each variable and outcome, the assumption of pro-
portional hazards was tested using a time-dependent covari-
ate. When this result indicated differential effects over time
(nonproportional hazards), models were constructed break-
ing the posttransplantation course into 2 time periods, using
the maximized partial likelihood method to find the most
appropriate breakpoint. Forward stepwise variable selection
at a 0.05 significance level was used to identify covariates
associated with the outcome. First-order interactions
between all signiﬁcant covariates were considered. Overall
covariate effects were tested using the Wald test. All P val-
ues are 2-sided.
RESULTS
Acute GVHD
The cumulative incidence of aGVHD by day 100 post-
transplantation was 33% (95% confidence interval [CI],
29%-38%) for grades II to IV aGVHD and 11% (95% CI,
9%-14%) for the severe form of the disease (≥grade III).
Independent risk factors for grades II to IV aGVHD that
were identified by the multivariate analysis included ABO
matching, the antibody used for TCD, and HLA matching
(Table 2).
Patients who had a minor ABO mismatch with the bone
marrow donor had a relative risk (RR) for aGVHD grades II
to IV of 2.0 (P < .001) compared with an ABO-identical
donor/recipient pair. However, neither a major ABO mis-
match nor a major-minor mismatch was associated with a
greater risk of aGVHD. This increased risk of aGVHD for
recipients of minor ABO-incompatible grafts was also seen
for patients with severe (≥grade III) aGVHD, as shown in
Figure 1. The 100-day cumulative incidence of grades II to
IV aGVHD was 28% (95% CI, 13%-44%) for the baseline
ABO-matched group, 48% (95% CI, 38%-58%) for the
minor mismatched group, 34% (95% CI, 24%-44%) for the
major mismatched group, and 28% (95% CI, 13%-44%)
for the major-minor mismatch group (P = .02). For severe
aGVHD, the cumulative incidences were 9% (95% CI,
6%-13%) for the baseline matched group, 20% (95% CI,
14%-28%) for the minor mismatched group, 11% (95% CI,
6%-18%) for the major mismatched group, and 7% (95% CI,
1%-19%) for the major-minor mismatched group (P = .05),
as shown in Figure 1.
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Beginning in 1998, due to the unavailability of an in
vivo–grade source of T10B9, our program switched to OKT3
for our complement-mediated lysis method of TCD. Com-
parison of grafts that were T cell depleted using T10B9 ver-
sus OKT3 revealed a lower log depletion of total clonable
T cells for the OKT3-treated grafts. Mean log depletion
was 1.94 (95% CI, 1.48-2.4) for T10B9 versus 1.69 (95% CI,
1.29-2.09), P < .01 for OKT3, resulting in a somewhat
larger T-cell dose (median 5.4 × 105/kg for OKT3 versus
3.4 × 105/kg for T10B9, P = .0005) for recipients of grafts
treated with OKT3. Because of concern over this higher
T-cell dose, we performed a univariate analysis of aGVHD
risk based on the antibody used for TCD. This analysis indi-
cated a significantly higher incidence of overall aGVHD,
48% (95% CI, 37%-58%) in the OKT3 group compared to
30% (95% CI, 26%-35%, P = .002) in the T10B9 group. Sim-
ilarly, the incidence of severe aGVHD was higher in the
OKT3 group, 22% (95% CI, 14%-32%) compared to 9%
(95% CI, 7%-12%) in the T10B9 group (P = .0005). This
ﬁnding was maintained after adjustment for other signiﬁcant
variables (including T-cell dose) in the multivariate analysis,
with an RR of grades II to IV aGVHD for the OKT3 group
that was 1.84 compared to the T10B9 group, P = .001.
Recipients of HLA-identical sibling transplants served
as the baseline group, with a cumulative incidence of grades
II to IV aGVHD of 18% (95% CI, 11%-26%) and of severe
aGVHD of 4% (95% CI, 2%-9%). There was no increased
risk of overall aGVHD compared with that in genetically
identical sibling transplantation for the group of patients
who received marrow from related donors who were
matched for 1 haplotype and either phenotypically identical
or mismatched for only 1 known HLA allele on the second
haplotype. However, recipients of related donor grafts who
were mismatched for 2 or more HLA alleles were at higher
risk for aGVHD (RR = 2.1, P = .005). Recipients of pheno-
typically HLA-identical UR donor grafts were also at
increased risk for aGVHD (RR = 1.98, P = .004). The high-
est RR of aGVHD was seen for recipients of UR donor
marrow with 2 or more identified HLA disparities (RR =
2.68, P = .003). Surprisingly, the risk of aGVHD for recipi-
ents of 1 Ag MM UR grafts was not signiﬁcantly different
from HLA-matched siblings in the multivariate analysis.
These results are shown graphically in Figure 3.
Chronic GVHD
Extensive cGVHD was evaluable in the 368 patients
who were alive and did not receive a second transplant,
donor leukocyte infusion, or other cellular immunotherapy
before day 90. Both patient age and cytomegalovirus (CMV)
status were identiﬁed as signiﬁcant independent variables in
the multivariate analysis (Table 3). Patients aged >20 years
were more likely to have extensive cGVHD (RR = 2.23, P <
.0001). CMV-seropositive patients who received transplants
from CMV-seronegative donors were the only group at
higher risk for extensive cGVHD compared with the base-
line CMV negative/negative group (RR = 1.86, P = .002).
Survival
The 3-year probability of survival for the group was
44% (95% CI, 40%-49%). The independent signiﬁcant risk
factors for survival by multivariate analysis were recipient
age, HLA-matching, risk, and recipient/donor CMV
serostatus at transplantation. These results are shown in
Table 4. The RR of death for patients aged >20 years was
1.63 compared to the baseline younger patients, P < .001.
Table 2. Multivariate Analysis for Acute GVHD
Variable RR (95% CI) P
ABO match
Matched 1.0 .002*
Minor mismatch 2.00 (1.37-2.92) <.001
Major mismatch 1.13 (0.73-1.74) .59
Major-minor mismatch 0.83 (0.39-1.74) .62
Antibody used for TCD
T10B9 1.0
OKT3 1.84 (1.27-2.67) .001
HLA mismatch
Genotypically matched related 1.0 .01†
0-1 Ag related 1.22 (0.50-2.97) .20
≥2 Ag related 2.09 (1.25-3.51) .005
Unrelated matched 1.98 (1.24-3.15) .004
1 Ag unrelated 1.28 (0.75-2.18) .37
≥2 Ag unrelated 2.68 (1.41-5.13) .003
*Three df test.
†Five df test.
Figure 1. Cumulative incidence of aGVHD based on ABO matching.
The cumulative incidence of aGVHD (grades II to IV) (A) and severe
aGVHD (≥grade III) (B) is shown based on ABO matching between
donor and recipient. The overall 100-day incidence of grades II to IV
GVHD is 33% and of severe aGVHD is 11%.
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Survival based on HLA matching and donor source was
compared to the genotypically HLA-identical sibling refer-
ence group. There was no signiﬁcant difference in survival
for patients receiving a graft from a 0 to 1 Ag MM related
donor or a fully matched UR donor. Recipients of grafts
from 1 Ag MM UR donors did have a higher risk of death
(RR = 1.62, P = .01). However, mismatching for 2 or more
HLA alleles was most strongly associated with decreased
survival for both recipients of related (RR = 2.12, P < .001)
and UR grafts (RR = 2.25, P = .001), as shown in Table 4
and illustrated in Figure 4A. The effect of HLA match
grade is also seen when the high-risk group is excluded from
the analysis, as shown in Figure 4B. CMV status at the time
of transplantation was associated with decreased survival
only for the combination CMV-negative donor to CMV-
positive recipient (RR = 1.50, P = .02) compared to the neg-
ative recipient, negative donor group after adjustment for
other variables. Decreased survival was also associated with
the disease risk group, with both intermediate- (RR = 1.48)
and high-risk groups (RR = 2.02) showing a signiﬁcant differ-
ence compared with the standard risk group. The survival of
the 34 patients who could not be assigned to a risk group
was not different from those in the standard risk group.
DISCUSSION
Several factors from our analysis were found to be associ-
ated with transplantation outcome after TCD BMT; some
were expected, and others not. As expected, a mismatch for
2 or more HLA alleles was associated with increased
aGVHD risk and lower survival rates, whereas older recipi-
ent age and CMV-negative donor to CMV-positive patient
grafts were associated with extensive cGVHD and lower sur-
vival rates. Likewise, survival was affected by the disease sta-
tus, with the highest survival rates seen for the standard risk
group. Somewhat unexpected were the ﬁndings that minor
ABO incompatibility and the antibody used for TCD were
independent risk factors for aGVHD. Also of significance
were the factors that were not associated with poor outcome
in our patient group. In particular, patient age was not asso-
ciated with an increased risk of aGVHD when analyzed as a
discrete variable or as a continuous variable (data not shown),
Figure 2. Effect of antibody used for TCD on aGVHD. The cumula-
tive incidence of aGVHD (grades II to IV) (A) and severe aGVHD
(≥grade III) (B) is shown, based on monoclonal antibody used for TCD.
Figure 3. Effect of HLA mismatching on aGVHD. The cumulative
incidence of aGVHD (grades II to IV) (A) and severe aGVHD (≥ grade
III) (B) is shown, based on HLA mismatch. RM indicates related
matched siblings; 0-1 RPM, 0 to 1 Ag MM related donor; ≥2 Rel, 2 or
more Ag MM related donor; UR, matched unrelated donor; 1 UR, 1
Ag MM unrelated donor; ≥2 UR, 2 or more Ag MM unrelated donor.
Table 3. Multivariate Analysis for Extensive Chronic GVHD
Variable RR (95% CI) P
Recipient age, y
≤20 1.0
>20 2.23 (1.60-3.10) <.001
Recipient-donor CMV status
Negative-negative 1.0 .15*
Negative-positive 1.26 (0.83-1.94) .28
Positive-negative 1.86 (1.25-2.77) .002
Positive-positive 1.35 (0.87-2.08) .18
*Three df test.
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even though such an association has been reported for older
patients receiving grafts that were not T cell depleted
[30,31]. Our approach of partial TCD may have eliminated
this age-associated increased risk of aGVHD and may have
permitted disparity at a single HLA allele without more
GVHD for recipients of both related and UR grafts.
Although recipients of matched UR donors had more
aGVHD, this ﬁnding did not translate to decreased overall
survival, and it resulted in only a marginally higher risk of
death for recipients of 1 Ag MM UR grafts.
The assessment of the relevance of HLA matches in
graft outcomes in our study as well as in most of the current
published studies is complicated both by the definition of
what constitutes a match and by the resolution of the tech-
niques used to define the HLA alleles. Our program was
among the first to adopt molecular techniques to define
HLA class II DRB1 and DQB alleles [32]. All of the
481 donor/recipient pairs included in this study underwent
molecular HLA-DRB1 and DQB typing either by oligotyp-
ing or DNA sequencing; thus, the typing at these loci was
well deﬁned. In contrast, class I HLA-A and HLA-B locus
alleles were defined only by serology in 165 (46%) of the
360 pairs who were not genotypically identical siblings. The
other 195 pairs were typed for HLA-A and HLA-B either
retrospectively (n = 130), using full-length DNA sequencing
[29] and/or 1-dimensional isoelectric focusing, or prospec-
tively (n = 65), by DNA sequencing of exons 2 and 3 to
provide a higher resolution of typing. Because of the retro-
spective class I typing, we identified 34 recipients of UR
donor grafts that were mismatched for 2 or more HLA alle-
les and could be included in the analysis as a separate group.
Although the HLA alleles were more fully typed in this study
than in most reported studies, the true degree of HLA allele
matching is not known for one third of 481 pairs for the
4 loci considered for matching. From a preliminary assess-
ment of patients that have been sequenced at HLA-A and
HLA-B, we would expect additional disparities in approxi-
mately 25% of the pairs thought to be matched by serology,
although few additional disparities were identiﬁed through
DRB1 or DQ sequencing compared with oligotyping
(unpublished observations). Given these caveats, we found
there was no signiﬁcant difference between the matched sib-
ling baseline group and the group with phenotypically iden-
tical or 1 Ag mismatched related donors in the risk of
aGVHD or the survival rate. However, the rates of aGVHD
and mortality were signiﬁcantly higher for recipients of both
related and UR donors if ≥2 HLA alleles were mismatched.
Recipients of matched UR donor grafts were at higher risk
of aGVHD than the matched sibling group, as has been pre-
viously reported [3], although this did not lead to increased
mortality. The increased risk of aGVHD in the matched UR
group might be explained by a higher degree of mismatch-
ing for minor histocompatibility antigens, because these
antigens are less likely to be matched between donor and
recipient outside the family setting. Unexpectedly, recipients
of 1 Ag MM UR donor grafts did not have a signiﬁcantly
higher risk of aGVHD in our study. Approximately 11% of
the patients in this group received ATG compared to 6% in
the UR matched group, a factor that might account for
some of the reduction in aGVHD. It could be argued that
residual host immunity might have targeted and eliminated
HLA-incompatible donor–derived T cells in this setting,
Table 4. Multivariate Analysis for Survival
Variable RR (95% CI) P
Recipient age, y
≤20 1.0
>20 1.63 (1.25-2.13) .001
HLA mismatch
Genotypically matched related 1.0 <.001*
0-1 Ag related 1.49 (0.81-2.75) .19
≥2 Ag related 2.12 (1.43-3.15) <.001
Unrelated matched 1.12 (0.78-1.62) .54
1 Ag unrelated 1.62 (1.10-2.37) .01
≥2 Ag unrelated 2.25 (1.38-3.69) .001
Recipient-donor CMV status
Negative-negative 1.0 .09†
Negative-positive 1.25 (0.89-1.76) .19
Positive-negative 1.50 (1.08-2.08) .02
Positive-positive 1.29 (0.90-1.84) .15
Disease risk group
Standard 1.0 <.001‡
Intermediate 1.48 (1.1-1.96) .008
High 2.02 (1.49-2.74) <.001
Others 0.83 (4.46-1.52) .55
*Five df test.
†Three df test.
‡Two df test.
Figure 4. Probability of survival based on HLA matching. The proba-
bility of survival based on HLA mismatch is shown for the entire dataset
(A) and with the exclusion of the 116 high-risk patients (B). The 3-year
overall survival rate for the entire group is 44% (95% CI, 40%-49%).
GVHD and Survival Following TCD Transplantation
627B B & M T
thus resulting in less aGVHD in this group than in the
HLA matched UR group. Unlike the matched UR group,
recipients of 1 Ag MM UR grafts were at a marginally
increased risk of death compared with the baseline matched
sibling group (RR = 1.6, P = .02). However, the validity of
these findings will require that the true class I identity of
both the matched UR and the 1 Ag MM UR groups be
resolved through high-resolution molecular typing. These
studies, additionally including the potential role of HLA-C
matching in transplantation outcome, are ongoing.
The effect of minor ABO incompatibility on the rate of
aGVHD was also unexpected. No differences in either
GVHD or survival rates were seen between ABO matched
donor/recipient pairs, major ABO mismatched pairs, or
major-minor ABO mismatch (A into B or B into A) pairs.
However, recipients of minor ABO mismatched grafts had
an RR of aGVHD twice that of the baseline ABO matched
pairs. A similar finding was reported by Bacigalupo et al.
[33] in a study of 174 recipients of unmodiﬁed marrow allo-
grafts, although earlier studies at other centers did not indi-
cate an association of ABO and aGVHD in this setting
[34,35]. In the Bacigalupo et al. study, ABO match was the
only significant correlate to grades II to IV aGVHD in a
Cox proportional hazard model, with recipients of minor
mismatched grafts having the highest incidence of aGVHD
(82%), whereas the ABO major mismatched group had the
lowest incidence (39%). However, in studies published
since 1988, ABO has rarely been indicated as a risk factor
for aGVHD [36], but most studies appear not to have
included ABO as a variable in these assessments. A recent
study published in abstract form by Stussi et al. did demon-
strate a higher risk of aGVHD associated with minor
ABO incompatibility (RR = 3.09, P = .005) in a study of
562 recipients of allogeneic hematopoietic stem cell trans-
plants [37], confirming our findings. ABO incompatibility
as a risk factor for survival after hematopoietic stem cell
transplantation has been described, with recipients of grafts
with a major ABO incompatibility having the worse out-
come [38-40]. Neither this finding nor decreased survival
rates in pairs with a major-minor mismatch as described by
Stussi was seen in our patient group. The mechanism
behind the association of minor ABO disparity with
aGVHD is not clear. It may be that the glycotransferase
enzymes coded for by the A or B genes not present in the
donor serve as minor histocompatibility antigens that can
be targets for T cells mediating aGVHD. However, our
own data argue against this hypothesis, because increased
aGVHD risk was not seen in patients with a bidirectional
mismatch. A role for donor-derived antibodies to A or
B blood group antigens is unlikely, because the processing
for TCD removes all donor plasma, and donor B-cell
engraftment and antibody production in recipients of TCD
grafts generally occurs outside the window for onset of
aGVHD [8,9]. Clearly, the signiﬁcance of ABO compatibility
as a risk factor for aGVHD requires further study to conﬁrm
our ﬁndings and those of Stussi et al. and Bacigalipo et al.
Given the strong statistical correlates found in the 3 studies
linking ABO matching to aGVHD, ABO matching should
be considered at the time of donor selection.
The third risk factor that was independently associated
with aGVHD in our study was the MoAb used for TCD.
The majority of transplantation performed at our center
used T10B9, a nonmitogenic immunoglobulin M murine
MoAb, as the purging reagent [29,41]. Our studies have indi-
cated that T10B9 binds to both T-cell receptor (TCR)αβ and
TCRγδ+ T cells at concentrations used for purging, when
ﬂow cytometry is performed using a biotinylated form of the
antibody [42]. If used as a ﬂuorescein isothiocyanate conju-
gate, T10B9 binding is restricted to TCRαβ+ T cells (unpub-
lished results; [43]), a phenomenon previously described for
other CD3-speciﬁc antibodies [44]. However, when T10B9 is
used to deplete T cells by complement-mediated lysis, the
TCRγδ+ T-cell subset is selectively spared (0.5 log depletion
versus 1.9 log depletion of the TCRαβ+ T-cell subset)
[19,42]. This selective sparing of TCRγδ+ T cells was not
seen for marrow TCD with OKT3 in our preclinical studies
[42] or in assessment of the grafts received by the patients in
this study (median 1.1 log depletion of TCRγδ+ T cells).
Despite the greater depletion of TCRγδ+ T cells by OKT3
in our hands, the overall degree of TCD using OKT3 was
found to be less than that attained with T10B9, resulting in a
larger median dose of T cells for recipients of grafts that
were T cell depleted with OKT3. In earlier studies restricted
to recipients of grafts that were T cell depleted using T10B9,
we identified T-cell dose as a risk factor for aGVHD in
recipients of related allografts but not in recipients of unre-
lated allografts [19]. In contrast, T-cell dose as a single factor
was not independently correlated with aGVHD in this study.
The reason for the higher risk of aGVHD in recipients of
grafts that were T cell depleted with OKT3 may reﬂect not
only the higher dose of T cells infused and a difference in
T-cell subset content, but also fact that OKT3 is mitogenic
and may actually stimulate and promote survival of the resid-
ual T cells. In contrast, the residual T cells in grafts that
were T cell depleted with T10B9 may be more likely to
undergo apoptosis and not survive to cause aGVHD [41].
Despite the higher rate of aGVHD, the MoAb used for
TCD was not an independent risk factor for survival.
The nature of cGVHD in the setting of partial TCD
may differ from conventional non-TCD transplantation.
Our own observation is that most patients, adult and pedi-
atric, with limited cGVHD are very responsive to therapy
and experience little morbidity as a result, as we have
reported for our pediatric patients [18]. For this reason, we
chose extensive cGVHD as our endpoint for assessing
cGVHD. Both older patient age (>20 years) and a positive
patient/negative donor CMV status at transplantation were
significant risk factors for cGVHD and for lower survival
rates. Older patient age has been widely described in a vari-
ety of transplantation settings as a risk factor for cGVHD
[45,46]. The reason is likely multifactorial and may involve
the impaired immune status of older patients as well as the
higher likelihood of preceding infectious complications, par-
ticularly with the herpes virus family [47,48]. Thymic func-
tion, in particular, is required for the generation of new
immune responses and for the development of speciﬁc T cells
that regulate the patient-directed alloreactivity of engrafted
donor T cells [49]. Recovery of thymic function, as repre-
sented by the appearance of naive CD4+ T-cell subsets [50]
and T-cell receptor excision circle (TREC)+ T cells [51], is
more impaired in older recipients of hematopoietic stem cell
transplants. TREC+ T-cell levels are especially low in
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patients with cGVHD [52,53]. Moreover, overall recovery of
immune function, both humoral and cellular, is superior in
younger patients. Younger age, together with better restora-
tion of thymic function, may contribute to the increased sur-
vival rates and lower likelihood of extensive cGVHD seen in
our study for patients aged ≤20 years [54-57].
Patients with a positive CMV status at the time of trans-
plantation have been previously described as having an
increased risk for aGVHD and a lower rate of survival fol-
lowing both conventional [58-61] and partially TCD trans-
plantation [62,63]. The association of a positive patient
CMV status with cGVHD has been less often described
[47]. We did not find an association between CMV status
and aGVHD in our TCD patient group. By univariate
analysis, we saw a higher rate of extensive cGVHD and
lower survival rates for CMV-positive recipients with either
CMV-positive or CMV-negative donors compared with
CMV-negative patients (not shown). However, after adjust-
ments for other significant variables, only the seropositive
recipients of seronegative marrow remained at a higher risk
for extensive cGVHD and lower survival rates. The associa-
tion of CMV and cGVHD may be explained by the pres-
ence of latent human CMV in many of the target organs for
cGVHD, including the liver, the spleen, and the endothe-
lium [64]. CMV infection may result in the up-regulation of
adhesion molecules secondary to inflammatory cytokine
production during periods of viral reactivation posttrans-
plantation [65,66]. The inflammatory cytokines produced
during CMV infection may help to initiate or intensify tis-
sue injury mediated by alloreactive donor-derived T cells,
thus leading to higher rates and/or degrees of cGVHD.
Indeed, preceding CMV infections have been found to be
associated with onset or exacerbation of cGVHD[48]. The
higher mortality of CMV-positive patients receiving trans-
plants from CMV-negative donors in our patient group may
reﬂect the need for prolonged immune suppression because
of cGVHD as well as the posttransplantation delay in recov-
ery of cellular and humoral immunity to CMV described for
such patients [67,68]. This characteristic would leave these
patients at higher risk for developing CMV disease and its
resultant morbidity and mortality [62,69].
Differences in significant risk factors for GVHD and
survival that were found in our patient group compared with
patients in other studies likely reﬂect the use of partial TCD
as well as other aspects of our conditioning and posttrans-
plantation regimens. We have demonstrated that the out-
come of TCD transplantation can be inﬂuenced by the anti-
body used for TCD, even within the narrow specificity
group deﬁned in the recent IBMTR study [4]. We and oth-
ers who perform transplantation using a similar approach
can use the ﬁndings of this study not only to better inform
patients, but also to identify treatment options that are more
likely to achieve the best outcomes. Our findings should
lead to improved algorithms for donor selection that con-
sider as favorable the choice of a CMV-positive donor for
CMV-positive patients and that avoid a minor ABO mis-
match. Improved HLA typing methods should allow us to
identify with more confidence donors with no more than
single HLA disparities and better avoid those with 2 or
more disparities, a donor characteristic that clearly compro-
mises outcomes. It is only through this process of identify-
ing risk factors for a particular patient group that improve-
ment in the quality of transplantation can be achieved.
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